L
Lisa Pleyer
Researcher at Paracelsus Private Medical University of Salzburg
Publications - 84
Citations - 1441
Lisa Pleyer is an academic researcher from Paracelsus Private Medical University of Salzburg. The author has contributed to research in topics: Azacitidine & Rituximab. The author has an hindex of 19, co-authored 75 publications receiving 1173 citations. Previous affiliations of Lisa Pleyer include Salk Institute for Biological Studies & Seattle Children's Research Institute.
Papers
More filters
Journal ArticleDOI
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
TL;DR: Progress made in understanding features of CLL biology are summarized and novel treatment strategies that have also been exploited in current clinical trials are described.
Journal ArticleDOI
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer,Sonja Burgstaller,Michael Girschikofsky,Werner Linkesch,Reinhard Stauder,Michael Pfeilstöcker,Martin Schreder,Christoph Tinchon,Thamer Sliwa,Alois Lang,Wolfgang R. Sperr,Peter Krippl,Dietmar Geissler,Daniela Voskova,Konstantin Schlick,Josef Thaler,Sigrid Machherndl-Spandl,Georg Theiler,Otto Eckmüllner,Richard Greil +19 more
TL;DR: Although currently not regarded as standard form of response assessment in AML, disease stabilization and/or HI should be considered sufficient response to continue treatment with azacitidine.
Journal ArticleDOI
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Peter Valent,Attilio Orazi,Michael R. Savona,Mrinal M. Patnaik,Francesco Onida,Arjan A. van de Loosdrecht,Detlef Haase,Torsten Haferlach,Chiara Elena,Lisa Pleyer,Wolfgang Kern,Tea Pemovska,Gregory I. Vladimer,Julie Schanz,Alexandra Keller,Michael Lübbert,Thomas Lion,Karl Sotlar,Andreas Reiter,Theo de Witte,Michael Pfeilstöcker,Klaus Geissler,Eric Padron,Michael W. Deininger,Alberto Orfao,Hans-Peter Horny,Peter L. Greenberg,Daniel A. Arber,Luca Malcovati,John M. Bennett +29 more
TL;DR: An international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions and proposed diagnostic standards and tools to distinguish between ‘normal’, pre- CMML and CMML entities.
Journal ArticleDOI
Digging deep into “dirty” drugs – modulation of the methylation machinery
Lisa Pleyer,Richard Greil +1 more
TL;DR: An overview of transcriptional regulation, including DNA methylation, post-translational histone-tail modifications, the role of micro-RNA and long-range epigenetic gene silencing, and the effect of HMAs on transcriptionalregulation is given.
Journal ArticleDOI
Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer,Reinhard Stauder,Sonja Burgstaller,Martin Schreder,Christoph Tinchon,Michael Pfeilstöcker,Susanne Steinkirchner,Thomas Melchardt,Martina Mitrovic,Michael Girschikofsky,Alois Lang,Peter Krippl,Thamer Sliwa,Alexander Egle,Werner Linkesch,Daniela Voskova,Hubert Angermann,Richard Greil +17 more
TL;DR: In this large cohort of AML-patients treated with azacitidine, age >80 years, number of comorbidities and/or BM-blasts >30% did not adversely impact OS and hematologic improvement alone alone was sufficient to confer OS benefit.